Pharmacovigilance study on drug-induced cardiac injury during treatment of COVID-19.
10.19540/j.cnki.cjcmm.20200322.503
- Author:
Dan ZHANG
1
;
Jin-Tao LYU
1
;
Bing ZHANG
2
;
Xiao-Meng ZHANG
1
;
Zhi-Jian LIN
1
Author Information
1. School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China.
2. School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China Center for Pharmacovigilance and Rational Use of Chinese Medicine, Beijing University of Chinese Medicine Beijing 102488, China.
- Publication Type:Journal Article
- Keywords:
2019-nCoV;
COVID-19;
antiviral drugs;
drug-induced heart injury;
pharmacovigilance;
rational administration of drug;
traditional Chinese medicine
- MeSH:
Betacoronavirus;
Cardiotoxicity;
Coronavirus Infections;
drug therapy;
Drugs, Chinese Herbal;
Heart Injuries;
chemically induced;
Humans;
Medicine, Chinese Traditional;
Pandemics;
Pharmacovigilance;
Pneumonia, Viral
- From:
China Journal of Chinese Materia Medica
2020;45(10):2275-2286
- CountryChina
- Language:Chinese
-
Abstract:
Because coronavirus disease 2019(COVID-19) is highly contagious and serious, it has posed a major threat to public health worldwide. The curative effects of integrated traditional Chinese medicine and Western medicine in the treatment of COVID-19 have been widely recognized and confirmed. However, medical workers shall pay attention to drug-induced heart injury in clinical application. Based on the guideline from the Diagnosis and Treatment Plans for COVID-19(trial seventh edition), taking the recommended drugs as examples, by Western medicine, traditional Chinese medicine, Chinese herbal injection and integrated traditional Chinese and Western medicine, the study analyzed the basic characteristics of recommended drugs for cardiac injury by means of literature review and bioinformatics methods, and summarized cardiac adverse reactions, toxicity mechanisms, combined pharmacotherapy, special population and drug monitoring, focusing on the clinical manifestations, toxic components, targets and regulatory mechanisms of drug-induced cardiac injury. The findings suggested being vigilant to drug-induced cardiac injury during the treatment of COVID-19, playing the advantages of clinical pharmacists and clinical Chinese pharmacists, improving the knowledge reserve of pharmacovigilance, strengthening the prescription review, medication notification and medication monitoring, promoting rational drug use and paying attention to special populations and high-risk groups. The study aims to provide suggestions and reference for pharmacovigilance and pharmaceutical care for front-line doctors and pharmacists against COVID-19, in order to avoid the occurrence of drug-induced heart injury for patients with COVID-19.
